BRAND-PACKAGE PREVIEW · Working visual direction for KFSHRC review · Pre-trademark · Do not redistribute

Cell & gene therapy manufacturing · Riyadh

Building Saudi Arabia's biotech renaissance.

Nahda Cellworks is an academic-hybrid contract development and manufacturing organisation for advanced therapy medicinal products, founded in collaboration with King Faisal Specialist Hospital & Research Centre under the National Biotechnology Strategy.

Founded with

Saudi Arabia's flagship Joint Commission-accredited academic medical centre — ranked No. 1 in the Middle East & Africa and 15th globally among academic medical centres (Brand Finance 2025), Newsweek World's Best Smart Hospitals 2025, the Kingdom's highest-volume cell-therapy program, with 50+ years of clinical-research leadership across oncology, transplantation, and genomic medicine.

Nahda Cellworks — heritage mark and bilingual wordmark lockup Saudi Vision 2030 — Kingdom of Saudi Arabia
View capabilities How we operate →
نهضة Nahda (نهضة) — the Arabic for renaissance and awakening. Names the Saudi national renewal opened by King Faisal's modernization programme and carried forward by Vision 2030. Biotech sovereignty as a chapter of that continuing renaissance.
Senior KFSHRC leaders cutting the cake at the King Faisal Specialist Hospital & Research Centre 50-year anniversary celebration in Riyadh, beneath the institution's bilingual heritage signature and 50 Years insignia.
KFSHRC · Fifty years · Riyadh 2025 Five decades of academic medical excellence — now extending into in-Kingdom cell-and-gene-therapy manufacturing.
16
GMP cleanrooms across 4 therapeutic clusters · Grade B background, Grade A for open manipulations
5,200 m²
Two-floor built-up area · modular cleanroom platform · commissioning Q1 2027
EU GMP
+ SFDA
EU Annex 1 (2023) contamination control · SFDA pre-engagement initiated 2026 · Royal Decree 54423
2,400
Doses per year at full operating capacity by 2030 · scaling from 100+ CAR-T treatments at Cluster 01 activation

Within the KFSHRC ecosystem

The parent system that anchors the Academic Hybrid CDMO.

Nahda Cellworks is the dedicated ATMP arm of King Faisal Specialist Hospital & Research Centre — Saudi Arabia's flagship tertiary/quaternary academic medical institution. Strategy, scientific direction, and patient pipelines flow through KFSHRC governance; manufacturing discipline, independent quality, and SFDA reporting flow through the standalone-entity board.

Aerial view of the King Faisal Specialist Hospital & Research Centre campus in Riyadh against the city skyline.

The KFSHRC campus, Riyadh

Saudi Arabia's flagship academic medical institution and the parent system of the Academic Hybrid CDMO. Source: KFSHRC / Arab News

KFSHRC recognitions

Newsweek World's Best Smart Hospitals 2025 badge featuring King Faisal Specialist Hospital and Research Centre

World's Best Smart Hospitals

2025

Newsweek · Statista

#1 Saudi Healthcare

Nature Index research output

2025

Nature Index

JCI Accredited

First JCI-accredited hospital in Saudi Arabia

Since 2002

Joint Commission International

Photographs depict the KFSHRC campus, exhibits, and public events. Sourced from KFSHRC press communications, Saudi Press Agency, and Global Health Exhibition 2024–2025 coverage. Recognitions cite original publishers (Newsweek/Statista, Nature Index, Joint Commission International). Used here for governance-context illustration on this brand-package preview; not a claim of endorsement.

Capabilities

The region's first multi-modal ATMP campus.

Nahda Cellworks is the MENA region's first integrated Advanced Therapy Medicinal Product (ATMP) manufacturing campus — a multi-modality cell and gene therapy facility supplying clinical and commercial-scale production for Saudi Arabia, the Middle East, and beyond. The facility activates in clusters, gated by capability and demand. Each suite is designed for multi-modal CGT production under a single quality system, a single tech-transfer methodology, and an independent quality reporting line — with regulatory alignment to SFDA, EMA, and FDA standards from day one.

CLUSTER 01

Adoptive Cell Therapies

CAR-T · Mesenchymal Stem Cells

Autologous and allogeneic CAR-T manufacturing alongside mesenchymal stem-cell (MSC) products. Closed-system processing built to clinical-batch scale with the analytics and release framework that makes each lot SFDA-credible.

  • Autologous & allogeneic CAR-T
  • Mesenchymal stem cell (MSC) products
  • Closed-system processing & cryopreservation
  • Release testing — flow, potency, sterility
CLUSTER 02

Gene Therapy & Vector Manufacturing

HSC gene therapy · LV & AAV vector

Haematopoietic stem-cell gene therapy for haemoglobinopathies and other priority indications, underwritten by in-house lentiviral and AAV vector manufacturing that serves both internal pipeline and regional academic demand.

  • HSC gene therapy (haemoglobinopathies focus)
  • Lentiviral (LV) vector — upstream & downstream
  • Adeno-associated virus (AAV) vector
  • Plasmid intermediates & vector analytics
CLUSTER 03+

Facility Expansion & Commercial Scale

Capacity for growth · Custom client work

Modular suites activated for contract development and manufacturing services to external sponsors, regional biotech partners, and the commercial scale-up of qualifying internal programs. Designed so growth never requires re-architecting the quality system.

  • Modular suite expansion for custom client work
  • Contract manufacturing & tech transfer
  • Commercial-scale batch capacity
  • Future-modality readiness (iPSC, gene editing)

Facility & Compliance

The campus, dimensions, and the regulatory frame the site operates under.

Cell-and-gene-therapy GMP cleanroom suite — operators in full cleanroom gowning working at biosafety cabinets in a Grade B background environment with Grade A critical zones.
Cell-and-gene-therapy GMP cleanroom suite — Grade B background, Grade A at biosafety cabinets
Footprint
5,200 m²

Two-floor built-up area. Modular cleanroom platform — factory-built, on-site assembled — accelerates commissioning and reduces construction risk. Operational handover Q1 2027.

Cleanroom matrix
16 + QC

16 GMP production suites — 4 per therapeutic cluster — plus dedicated QC laboratories, cold storage at −196 °C, and warehouse zones. All production suites: Grade B background with Grade A critical zones at biosafety cabinets.

Classification
EU GMP B/A

EU GMP Grade B background with Grade A for open manipulations, supported by ISO 7 / ISO 5 BSC environments. Closed-system processing where modality permits — reducing classification burden and contamination risk.

Operating compliance framework

  • Multi-regulator alignment — SFDA, EMA, FDA, and BMBL requirements built into the facility URS
  • EU GMP Annex 1 (2023) — contamination control strategy
  • SFDA pre-engagement program initiated 2026 — Saudi marketing-authorisation pathway
  • ICH Q-series & ICH Q5/Q9/Q10 — quality, risk, and lifecycle management
  • Royal Decree 54423 — establishes KFSHRC ATMP manufacturing facility authorisation
  • National Biotechnology Strategy alignment — Vision 2030 industrial pillar to position the Kingdom as a global biotech hub by 2040
  • Independent QA reporting line — outside operations, direct to standalone-entity board through 2030

The Academic-Hybrid model

Three zones, one program.

Discovery and manufacturing require fundamentally different mindsets. The Wall is the structural separation that preserves discovery velocity on one side and manufacturing discipline on the other — connected by governed handoffs and independent quality reporting.

Zone 01

Research

Discovery-driven sandbox. Hospital and academic collaborators on TRL 1–5 work, with industry partner co-development.

  • Hypothesis-driven mindset
  • Reports to CSO / VP Research
  • KPIs: hypotheses, publications, IP
Zone 02

Non-GMP Development

Process development at lab scale. Scale-up engineering trials, analytical method development, tech-transfer documentation.

  • Hypothesis → process mindset
  • Bridges discovery and manufacturing
  • KPIs: tech-transfer readiness
Zone 03

GMP Manufacturing

Validated manufacturing only. Batch release, quality systems, SFDA cadence, independent QA reporting line outside operations.

  • Every batch the same
  • Reports to Site Head + independent QA
  • KPIs: batch success, zero major obs

How we are governed

Patient · Sustainability · Prominence.

Three anchors decide every modality, every contract, every capacity request. A neither-hospital-nor-pure-CDMO operating model — the only structure that protects all three simultaneously.

Why neither model alone works

Hospital pharmacy lacks scale and cadence. Tech transfer becomes improvised; partnership credibility never accrues; patient mission becomes capacity-bound.

Pure CDMO disconnects from mission. The clinical-research loop severs; patient priority becomes secondary to margin; the Vision 2030 anchor role is forfeited.

Hybrid Academic-CDMO is a new species for cell therapy: research-anchored, GMP-disciplined, patient-led, partner-orchestrating. The competitive moat capacity cannot match.

The decision architecture

Every modality, partnership, and capacity request passes three filters in order:

Filter 01 · Clinical fit. Real patient need at KFSHRC plus credible capability today, or an obvious extension of it.

Filter 02 · Demand and sustainability. Credible volume path that pays its own way within the activation horizon.

Filter 03 · Strategic anchor. Strengthens the regional ATMP hub identity and serves the National Biotechnology Strategy.

Three passes → yes. Two → not yet, with conditions. One or zero → not now. The framework decides; the framework is the answer.

Leadership

KFSHRC governance over a site team announced at commissioning.

The facility is sponsored by King Faisal Specialist Hospital & Research Centre, with executive oversight through KFSHRC leadership and a dedicated ATMP Program Committee. Site Head and Quality Site Head report independently to the standalone-entity board through 2030, after which the facility re-integrates into KFSHRC governance under the ATMP Program Committee. Operating-team announcements are timed to facility commissioning gates.

His Excellency Dr. Majid I. Al Fayyadh, MD, MMM

His Excellency

Dr. Majid I. Al Fayyadh, MD, MMM

Chief Executive Officer & Board Member

King Faisal Specialist Hospital & Research Centre

Pediatric cardiologist and electrophysiologist appointed CEO in 2017. Leads KFSHRC's Vision 2030 transformation across oncology, transplantation, genomics, and cell & gene therapy. Previously advisor to the Vision Realization Office, Saudi Ministry of Health.

LinkedIn
Dr. Osama Alswailem, MD, MA, Cert.Dir

KFSHRC Executive

Dr. Osama Alswailem, MD, MA, Cert.Dir

Assistant to the Chief Executive Officer

King Faisal Specialist Hospital & Research Centre

Senior physician-executive bridging medical informatics, clinical operations, and CEO-office strategy. Former Chief Information Officer / Chief Medical Information Officer at KFSHRC; Harvard Business School AMP graduate; certified director.

LinkedIn
Site Head portrait — illustrative imagery

Operating Team

Site Head

General Management

Reports to the standalone-entity board

Operator-provided through Years 1–3 under the Build-Operate-Transfer mandate. Saudi successor in 1:1 pairing from Year 3 onward.

Announcement Q3 2026
Quality Site Head portrait — illustrative imagery

Operating Team

Quality Site Head

Independent Quality

Reports outside operations, board-direct

Independent reporting line to the standalone-entity board. Saudi successor pairing matches site-leadership cadence; quality independence preserved through the transition.

Announcement Q4 2026
Commercial Lead portrait — illustrative imagery

Operating Team

Commercial Lead

In-Licensing & CDMO BD

Saudi-track from day one

Owns the BD pipeline, in-licensing negotiations, CDMO contract evaluation, and out-licensing of KFSH-developed IP. Sits inside the standalone entity through 2030.

Announcement H1 2027

KFSHRC parent-institution leadership shown for governance reference; public titles and photos drawn from official sources, with engagement contingent on KFSHRC executive approval. Operating-team portraits are illustrative imagery for the working brand preview — final photography will replace these placeholders following the scheduled announcements.

Insights

The thinking behind the facility.

May 2026 · Operating Plan

Why a hybrid academic-CDMO is the only structure that protects all three anchors.

Patient mission, financial sustainability, and regional prominence cannot all be served by a hospital pharmacy or a pure CDMO. The hybrid is the structural answer — not a compromise.

Read the framing →
April 2026 · Capability brief

Lentiviral vector self-sufficiency: the case for Cluster 02 in 2027.

Allogeneic platforms, gene editing beyond Casgevy, and Saudi haplobank programs all converge on a single capability: regional LV vector supply. The case for activating Cluster 02 alongside Cluster 01.

Read the brief →
March 2026 · Heritage

From King Faisal's modernization to Vision 2030 biotech sovereignty.

Saudi Arabia's renewal is half a century old — public education, KFSHRC's founding in 1975, the modern medical research base. Nahda Cellworks is the biotech chapter of that continuing nahda.

Read the essay →

Partner with us.

For in-licensing enquiries, CDMO contract discussion, or academic collaboration on advanced therapies in the MENA region.

partner@nahdacellworks.com